Quarterly ResultMay 12, 2026, 04:39 PM
Vireo Growth Q1 Revenue $106.2M; Net Loss $20.3M; Medical Cannabis Rescheduled
AI Summary
Vireo Growth Inc. reported a significant increase in Q1 2026 revenue, reaching $106.2 million, up 335% year-over-year. However, the company's net loss widened to $20.3 million for the quarter. A major development impacting the cannabis industry is the DEA's final rule on April 28, 2026, rescheduling state-licensed medical marijuana to Schedule III, which could provide significant tax relief by allowing deduction of ordinary business expenses. Additionally, Vireo Growth completed the acquisition of Schwazze assets on March 19, 2026, expanding its footprint with 45 dispensaries and two manufacturing facilities.
Key Highlights
- DEA rescheduled state-licensed medical marijuana to Schedule III on April 28, 2026.
- This change may allow medical cannabis entities to deduct ordinary business expenses.
- Q1 2026 revenue increased 335% to $106.2 million from $24.5 million in Q1 2025.
- Q1 2026 net loss widened to $20.3 million from $6.5 million in Q1 2025.
- Acquired Schwazze assets on March 19, 2026, including 45 dispensaries and 2 manufacturing facilities.
- Cash and restricted cash was $137.8 million at March 31, 2026.
- Total assets grew to $928.8 million at March 31, 2026.
- Retail revenue rose to $89.9 million in Q1 2026.